Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Leticia Tetteh"'
Autor:
Mary Pinder-Schenck, Angela Akar, Charles C. Williams, Alberto Chiappori, Jenny Kreahling, Julie A. Kish, Soner Altiok, Jhanelle E. Gray, Eric B. Haura, Richard Lush, Leticia Tetteh, Tawee Tanvetyanon, Xiuhua Zhao, Michael J. Schell, Gerold Bepler, Anthony Neuger
Publikováno v:
Clinical Cancer Research. 20:1644-1655
Purpose: Panobinostat, a histone deacetylase (HDAC) inhibitor, enhances antiproliferative activity in non–small cell lung cancer (NSCLC) cell lines when combined with erlotinib. We evaluated this combination in patients with advanced NSCLC and head
Autor:
Melissa S. Thebeau, Geoffrey T. Gibney, Ragini R. Kudchadkar, Jeffrey S. Weber, Cabell Eysmans, H. David Inzunza, Maria P. Czupryn, Leticia Tetteh, Kate Fisher, Ronald C. DeConti, Alberto J Martinez, Christine Horak, Michael J. Schell, Allison Richards, Ibrahim Younos, Bin Yu
Purpose: The anti-programmed death-1 (PD-1) antibody nivolumab (BMS-936558) has clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was investigated as adjuvant therapy in resected stage IIIC and IV melanoma patients. Exper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eed3763189ea926d47974a58f0920f2f
https://europepmc.org/articles/PMC4620684/
https://europepmc.org/articles/PMC4620684/
Autor:
J. Joseph Mahany, Jeannine S. McCune, A. Benjamin Suttle, Linda L. Garland, Daniel M. Sullivan, Leticia Tetteh, Richard Lush, John A. Thompson
Publikováno v:
Cancer Chemotherapy and Pharmacology. 56:578-584
Due to advances in the methods used to quantitate vinorelbine, this study was conducted to characterize fully the bioavailability of an oral dosage form of vinorelbine. Twenty-seven eligible patients with solid tumors were enrolled onto this study an
Autor:
Ann Chen, Howida Ramadan, Geoffrey T. Gibney, Ragini R. Kudchadkar, Xiuhua Zhao, Zeynep Eroglu, Jane L. Messina, Jeffrey S. Weber, Keiran S.M. Smalley, John M. Koomen, Nikhil I. Khushalani, Joseph Markowitz, Ritin Sharma, Leticia Tetteh, Vernon K. Sondak
Publikováno v:
Journal of Clinical Oncology. 34:9544-9544
9544Background: BRAF inhibitors are clinically active in advanced BRAFV600 mutant melanoma patients, but resistance is common. Multiple resistance mechanisms involve HSP90 clients and preclinical d...
Autor:
Michael J. Schell, George R. Simon, Alberto Chiappori, Anthony Neuger, Jhanelle E. Gray, Scott J. Antonia, Charles Williams, Sharon Litschauer, Lanxi Song, Gerold Bepler, Bhupendra Rawal, Eric B. Haura, Tawee Tanvetyanon, Leticia Tetteh
Purpose Src family kinase (SFK) proteins are frequently activated in cancer and can coordinate tumor cell growth, survival, invasion, and angiogenesis. Given the importance of SFK signaling in cancer, known cooperation between SFK and epidermal growt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d55d2570aef18f3eca057bd9b5fd420
https://europepmc.org/articles/PMC3040065/
https://europepmc.org/articles/PMC3040065/
Autor:
Alan B. Cantor, Caio Rocha-Lima, George R. Simon, Richard Lush, Mayer Fishman, Daniel M. Sullivan, Jana L. Gump, Scott J. Antonia, Charles Williams, Leticia Tetteh, Christopher R. Garrett, Pamela N. Munster
Publikováno v:
Molecular cancer therapeutics. 5(8)
Purpose: Resistance to topoisomerase (topo) I inhibitors has been related to down-regulation of nuclear target enzyme, whereas sensitization to topo II inhibitors may result from induction of topo II by topo I inhibitors. Here, we evaluated a sequenc
Autor:
Geoffrey T. Gibney, Cabell Eysmans, Jeffrey S. Weber, Leticia Tetteh, Alberto J Martinez, Ragini R. Kudchadkar, Ibrahim Younos, Bin Yu, Ronald C. De Conti
Publikováno v:
Journal of Clinical Oncology. 31:9056-9056
9056^ Background: Nivolumab (BMS-936558), a fully human monoclonal antibody targeting the programmed death-1 (PD-1) receptor, has demonstrated clinical activity in advanced metastatic melanoma patients (pts). In this phase I study, the safety and act
Autor:
George R. Simon, Richard Lush, Daniel M. Sullivan, J. J. Mahany, Leticia Tetteh, L. Kvols, Alberto Chiappori
Publikováno v:
Journal of Clinical Oncology. 22:2132-2132
2132 Background. Carboplatin(C), Irinotecan(T) and Etoposide (E) are drugs with a broad spectrum of activity. Synergism has been demonstrated between a platinum compound and a top I inhibitor. Addi...